Relypsa (RLYP) has an average broker rating of 2.4, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Relypsa (RLYP) : 7 Wall Street analysts covering Relypsa (RLYP) believe that the average level the stock could reach for the short term is $32.43. The maximum price target given is $51 and the minimum target for short term is around $20, hence the standard deviation is calculated at $9.86.
For the current week, the company shares have a recommendation consensus of Buy.
Relypsa (NASDAQ:RLYP): The stock opened at $31.88 on Wednesday but the bulls could not build on the opening and the stock topped out at $31.92 for the day. The stock traded down to $31.86 during the day, due to lack of any buying support eventually closed down at $31.91 with a loss of -0.09% for the day. The stock had closed at $31.94 on the previous day. The total traded volume was 1,386,018 shares.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.